Home Articles List Article Information
Research in Oncology
Journal Archive
Volume Volume 21 (2025)
Volume Volume 20 (2024)
Volume Volume 19 (2023)
Volume Volume 18 (2022)
Volume Volume 17 (2021)
Volume Volume 16 (2020)
Volume Volume 15 (2019)
Volume Volume 14 (2018)
Volume Volume 13 (2017)
Volume Volume 12 (2016)
Gohar, S., Al-Hassanin, S., Shehata, A., Soliman, S. (2018). Clinical Value of Serum Neopterin in Breast Cancer. Research in Oncology, 14(2), 70-74. doi: 10.21608/resoncol.2018.4153.1061
Suzy F. Gohar; Suzan A. Al-Hassanin; Amira M. Shehata; Shaimaa S. Soliman. "Clinical Value of Serum Neopterin in Breast Cancer". Research in Oncology, 14, 2, 2018, 70-74. doi: 10.21608/resoncol.2018.4153.1061
Gohar, S., Al-Hassanin, S., Shehata, A., Soliman, S. (2018). 'Clinical Value of Serum Neopterin in Breast Cancer', Research in Oncology, 14(2), pp. 70-74. doi: 10.21608/resoncol.2018.4153.1061
Gohar, S., Al-Hassanin, S., Shehata, A., Soliman, S. Clinical Value of Serum Neopterin in Breast Cancer. Research in Oncology, 2018; 14(2): 70-74. doi: 10.21608/resoncol.2018.4153.1061

Clinical Value of Serum Neopterin in Breast Cancer

Article 5, Volume 14, Issue 2, December 2018, Page 70-74  XML PDF (282.64 K)
Document Type: Original Article
DOI: 10.21608/resoncol.2018.4153.1061
View on SCiNiTO View on SCiNiTO
Authors
Suzy F. Gohar email orcid 1; Suzan A. Al-Hassanin1; Amira M. Shehata2; Shaimaa S. Soliman3
1Clinical Oncology Department, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt
2Clinical Pathology Department, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt
3Public Health and Community Medicine Department, Faculty of Medicine, Menoufia University, Shebin Elkom, Egypt
Abstract
Background: The immune marker neopterin may have a prognostic role in different cancers including breast cancer.
Aim: To assess the relation between pre-chemotherapy serum level of neopterin and the clinical and pathological features of breast cancer patients.
Methods:Sixty-three patients with histologically confirmed breast cancer and 20 healthy females matched for age and sex as controls were included. All patients were subjected to full history taking, thorough medical examination and complete investigation. Venous blood samples were collected from all participants to measure serum neopterin level. Serum neopterin level more than 10 nMol\L was considered elevated.
Results: The mean serum neopterin level among patients was 8 ± 7.43. Twenty-two patients (34.9%) had elevated serum neopterin level. Neopterin was found to be significantly elevated in patients with advanced stages and grade III tumors. Metastatic disease was associated with significantly higher levels of neopterin (p = 0.04). There was no significant association between high neopterin level and mean time to progression or overall survival.
Conclusion:Among breast cancer patients, the immune marker neopterin was significantly related to metastatic disease and it could be considered a potential marker for systemic spread of the tumor.
Keywords
breast cancer; Metastatic disease; prognosis; Neopterin
Statistics
Article View: 532
PDF Download: 668